<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7066069\results\search\tropicalVirus\results.xml">
  <result pre="Research Liposomal Delivery of the RNA Genome of a Live-Attenuated" exact="Chikungunya" post="Virus Vaccine Candidate Provides Local, but Not Systemic Protection"/>
  <result pre="is permitted which does not comply with these terms. Abstract" exact="Chikungunya" post="virus (CHIKV) is the causative pathogen of chikungunya fever,"/>
  <result pre="progress to chronic arthritis. Our previous studies have identified the" exact="CHIKV" post="live-attenuated vaccine candidate CHIKV-NoLS. Like most live-attenuated vaccines, attenuated"/>
  <result pre="viremia and disease signs representative of this lethal model of" exact="CHIKV" post="infection, demonstrating de novo vaccine particle production in vivo."/>
  <result pre="of liposome-delivered CHIKV-NoLS RNA did not provide systemic protection from" exact="CHIKV" post="wild-type (WT) challenge but was found to promote an"/>
  <result pre="of CHIKV-WT-challenged mice. These results support previous studies that suggest" exact="CHIKV" post="is vulnerable to antibody-mediated enhancement of disease. Further studies"/>
  <result pre="of Primary Industries10.13039/100010000 fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction" exact="Chikungunya" post="fever is a mosquito-borne viral disease caused by the"/>
  <result pre="a mosquito-borne viral disease caused by the chikungunya virus (CHIKV)." exact="CHIKV" post="is a positive-sense single-stranded RNA (+ssRNA) virus and has"/>
  <result pre="2005–2006) and India (3–4 million estimated cases in 2005–2011) (1–3)." exact="CHIKV" post="has recently become established in the Americas, infecting over"/>
  <result pre="just 2 years (4). The majority of individuals infected with" exact="CHIKV" post="develop disease (5, 6). Symptoms of chikungunya disease are"/>
  <result pre="lasting several weeks to years (7). This chronic form of" exact="CHIKV" post="disease contributes considerably to disease burden. Atypical presentations associated"/>
  <result pre="disease contributes considerably to disease burden. Atypical presentations associated with" exact="CHIKV" post="infection include hepatitis, Guillain-Barré syndrome, myocarditis, retinitis, and nephritis"/>
  <result pre="nephritis (8). Increases in mortality have been described in several" exact="CHIKV" post="epidemics with most deaths occurring in neonates, patients with"/>
  <result pre="available. Our previous studies report the development of a live-attenuated" exact="CHIKV" post="vaccine candidate CHIKV-NoLS (12, 13). Mutating the nucleolar localization"/>
  <result pre="CHIKV-NoLS (12, 13). Mutating the nucleolar localization sequence (NoLS) of" exact="CHIKV" post="capsid protein, replacing 10 wild-type (WT) amino acids with"/>
  <result pre="of mice with one dose of CAF01-delivered CHIKV-NoLS RNA produced" exact="CHIKV" post="neutralizing antibodies and provided regional protection from disease following"/>
  <result pre="CHIKV neutralizing antibodies and provided regional protection from disease following" exact="CHIKV" post="challenge. This study provides the basis for developing CAF01-mediated"/>
  <result pre="RNA as a vaccine strategy. Further characterization of the live-attenuated" exact="CHIKV" post="vaccine candidate CHIKV-NoLS demonstrates the high degree of attenuation"/>
  <result pre="foot. The immunologically competent C57BL/6 mouse footpad model of acute" exact="CHIKV" post="disease recapitulates the arthritis, tenosynovitis, and myositis associated with"/>
  <result pre="0.05 was considered to be significant. Results CAF01 Delivers Replication-Competent" exact="CHIKV" post="RNA in vitro To overcome potential production limits for"/>
  <result pre="RNA in vitro To overcome potential production limits for our" exact="CHIKV" post="vaccine candidate (CHIKV-NoLS), we developed a liposomal approach to"/>
  <result pre="infection (Figure 1B). Cells transfected with RNA alone showed no" exact="CHIKV" post="infectivity and no signs of cytopathic effect (tested up"/>
  <result pre="transfection). Results demonstrate that CAF01 is able to deliver replication-competent" exact="CHIKV" post="RNA in vitro. Cell transfected with CHIKV-WT CAF01 began"/>
  <result pre="transfection (data not shown). To examine the productive replication of" exact="CHIKV" post="following CHIKV-WT CAF01 transfection, growth kinetics were analyzed by"/>
  <result pre="by plaque assay. CHIKV-WT CAF01 transfected cells produced live infectious" exact="CHIKV" post="with increasing titer to 53 h post transfection (Figure"/>
  <result pre="CHIKV-WT RNA showed signs of cytopathic effect and produced high" exact="CHIKV" post="titers earlier than cells transfected with CHIKV-WT CAF01. Cells"/>
  <result pre="(Figure 2A). Results suggest CAF01 is able to deliver replication-competent" exact="CHIKV" post="RNA in vivo to produce viable infectious CHIKV particles."/>
  <result pre="deliver replication-competent CHIKV RNA in vivo to produce viable infectious" exact="CHIKV" post="particles. Figure 2 Inoculation with CHIKV-NoLS CAF01 elicits de"/>
  <result pre="Signs but Recover From Infection As a lethal model of" exact="CHIKV" post="infection, the attenuation of CHIKV-NoLS CAF01 was tested in"/>
  <result pre="Mice Survive CHIKV-WT Challenge and Are Protected From Development of" exact="CHIKV" post="Disease As CHIKV-NoLS CAF01-inoculated AG129 mice survived, AG129 mice"/>
  <result pre="performed by non-parametric Mann–Whitney t-test. CHIKV-NoLS CAF01 Inoculation Protects Against" exact="CHIKV" post="Disease in the Ipsilateral Foot of C57BL/6 Mice Challenged"/>
  <result pre="5A–C). Results suggest that CHIKV-NoLS immunization provides systemic protection from" exact="CHIKV" post="challenge after one dose. All mice inoculated with either"/>
  <result pre="challenge (Figures 5A–C). Figure 5 CHIKV-NoLS CAF01 inoculation protects against" exact="CHIKV" post="disease in the ipsilateral foot of C57BL/6 mice upon"/>
  <result pre="CHIKV-NoLS CAF01 immunization provides local but not systemic protection from" exact="CHIKV" post="challenge. Cellular Infiltration in Challenged C57BL/6 Mice To further"/>
  <result pre="feet of CHIKV-NoLS RNA-inoculated mice compared to mock-infected controls following" exact="CHIKV" post="challenge (Figures 6B,C). For both activated neutrophils and inflammatory"/>
  <result pre="CHIKV-WT-inoculated group, which was protected from development of swelling upon" exact="CHIKV" post="challenge. This suggests that activated neutrophils and inflammatory monocytes"/>
  <result pre="groups compared to unchallenged controls also emphasizes their involvement in" exact="CHIKV" post="disease. Together, these data suggest that cellular infiltrates, particularly"/>
  <result pre="inflammatory monocytes, are involved in the early onset of severe" exact="CHIKV" post="disease in CHIKV-NoLS RNA-challenged mice. Figure 6 Cellular infiltration"/>
  <result pre="challenged with CHIKV. Antibody Response in CHIKV-NoLS CAF01-Inoculated C57BL/6 Mice" exact="CHIKV" post="vaccine studies in mice and non-human primates indicate that"/>
  <result pre="site (21). Interestingly, CHIKV-NoLS CAF01-inoculated C57BL/6 mice, although protected from" exact="CHIKV" post="disease when challenged at the site of inoculation, did"/>
  <result pre="the site of inoculation, did not develop systemic protection from" exact="CHIKV" post="challenge. In fact, an early onset of severe disease"/>
  <result pre="mice. This enhancement of inflammation has been observed in previous" exact="CHIKV" post="vaccination strategies and likened to a phenomenon known as"/>
  <result pre="of CHIKV-specific antibodies, demonstrating the role of antibody-mediated enhancement during" exact="CHIKV" post="infection and pathogenesis (30). With significantly low levels of"/>
  <result pre="mechanisms, in addition to neutralizing antibodies, mediate local protection from" exact="CHIKV" post="disease in mice. Further studies are ongoing to evaluate"/>
  <result pre="2005-2006. Am J Trop Med Hyg. (2007) 77:727–31. 10.4269/ajtmh.2007.77.72717978079 3.BeesoonSFunkhouserEKoteaNSpielmanARobichtRM." exact="Chikungunya" post="fever, Mauritius, 2006. Emerg Infect Dis. (2008) 14:337–8. 10.3201/eid1402.07102418258136"/>
  <result pre="2006. Emerg Infect Dis. (2008) 14:337–8. 10.3201/eid1402.07102418258136 4.Van BortelWDorleansFRosineJBlateauARoussetDMatheusSet al.." exact="Chikungunya" post="outbreak in the Caribbean region, December 2013 to March"/>
  <result pre="chikungunya virus infection. Lancet Infect Dis. (2008) 8:2–3. 10.1016/S1473-3099(07)70294-318156079 6.SimonFJavelleEOliverMLeparc-GoffartIMarimoutouC." exact="Chikungunya" post="virus infection. Curr Infect Dis Rep. (2011) 13:218–28. 10.1007/s11908-011-0180-121465340"/>
  <result pre="chikungunya epidemic of 2014. Epidemiol Infect. (2018) 146:2059–65. 10.1017/S095026881800231530152293 10.StaplesJEBreimanRFPowersAM." exact="Chikungunya" post="fever: an epidemiological review of a re-emerging infectious disease."/>
  <result pre="by Foroderm. Vaccine. (2015) 33:5172–80. 10.1016/j.vaccine.2015.07.09926296498 29.HallengardDKakoulidouMLullaAKummererBMJohanssonDXMutsoMet al.. Novel attenuated" exact="Chikungunya" post="vaccine candidates elicit protective immunity in C57BL/6 mice. J"/>
 </snippets>
</snippetsTree>
